- Home
- RFI vs CRVS Comparison
RFI vs CRVS Comparison
Compare RFI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFI
- CRVS
- Stock Information
- Founded
- RFI 1992
- CRVS 2014
- Country
- RFI United States
- CRVS United States
- Employees
- RFI N/A
- CRVS N/A
- Industry
- RFI Investment Managers
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- RFI Finance
- CRVS Health Care
- Exchange
- RFI Nasdaq
- CRVS Nasdaq
- Market Cap
- RFI 323.2M
- CRVS 305.4M
- IPO Year
- RFI N/A
- CRVS 2016
- Fundamental
- Price
- RFI $12.10
- CRVS $5.75
- Analyst Decision
- RFI
- CRVS Strong Buy
- Analyst Count
- RFI 0
- CRVS 4
- Target Price
- RFI N/A
- CRVS $15.00
- AVG Volume (30 Days)
- RFI 69.8K
- CRVS 518.7K
- Earning Date
- RFI 01-01-0001
- CRVS 08-07-2025
- Dividend Yield
- RFI 8.25%
- CRVS N/A
- EPS Growth
- RFI N/A
- CRVS N/A
- EPS
- RFI N/A
- CRVS N/A
- Revenue
- RFI N/A
- CRVS N/A
- Revenue This Year
- RFI N/A
- CRVS N/A
- Revenue Next Year
- RFI N/A
- CRVS N/A
- P/E Ratio
- RFI N/A
- CRVS N/A
- Revenue Growth
- RFI N/A
- CRVS N/A
- 52 Week Low
- RFI $9.62
- CRVS $2.54
- 52 Week High
- RFI $12.52
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- RFI 52.30
- CRVS 65.10
- Support Level
- RFI $11.89
- CRVS $5.28
- Resistance Level
- RFI $12.07
- CRVS $5.64
- Average True Range (ATR)
- RFI 0.09
- CRVS 0.30
- MACD
- RFI 0.01
- CRVS 0.03
- Stochastic Oscillator
- RFI 60.71
- CRVS 77.70
About RFI Cohen & Steers Total Return Realty Fund Inc.
Cohen & Steers Total Return Realty Fund Inc is a diversified, closed-end management investment company. Its investment objective is to achieve a high total return through investment in real estate securities. The Fund invests majority of its total assets in the equity securities of real estate companies under normal circumstances, which includes common shares, REITs, rights or warrants, convertible securities, and preferred shares.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).